An Immunotherapy Vaccine (PIpepTolDC) for the Treatment of Patients With Type 1 Diabetes

City of Hope

Status and phase: Active, not recruiting; Phase 1

Conditions: Type 1 Diabetes Mellitus

Treatments: Biological: Tolerogenic Dendritic Cell Vaccine

Study type: Interventional

Funder types: Other

Identifiers

NCT04590872

18279

Details and patient eligibility

About

This phase I trial investigates the side effects of PIpepTolDC vaccine in treating patients with type 1 diabetes who use insulin and don't have any other diabetes-related health complications. Type 1 diabetes is an autoimmune disease. This means that the immune system, which usually protects against foreign invaders like bacteria and viruses, attacks the body's insulin-producing betacells in the pancreas (autoimmune response). Overtime, the beta cells are destroyed by the immune system. To stay alive, people with type 1 diabetes must use insulin. PIpepTolDC vaccine is a type of immunotherapy (a treatment that uses a person's own immune system) that works like an allergy shot. The vaccine is made using one's own immune cells (dendritic cells) and a beta cell protein. The vaccine may teach the immune system to stop attacking the beta cells, which may help the beta cells recover and make enough insulin to control blood sugar levels. The vaccine may also help reduce future type 1 diabetes related complications.

Enrollment: 6 patients

Sex: All

Ages: 18 to 45 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Willingness to undergo leukapheresis

• Willingness to be followed for about 2 years post-prime dose

• For participants who have a personal continuous glucose monitoring device (CGMD): Willingness to wear a second CGMD during mandated study CGMD visits

• Diagnosis of type 1 diabetes based on American Diabetes Association (ADA) criteria

• Historical presence of at least one type-1 diabetes associated autoantibody

  • GAD specific autoantibodies (glutamic acid decarboxylase autoantibodies [GADA])
  • Islet cell cytoplasmic autoantibodies (ICA)
  • Islet-antigen 2 specific autoantibody (IA-2A)
  • Zinc transporter 8 specific autoantibody (ZNT8A); and/or
  • Insulin autoantibody (IAA) (must have been obtained within 7 days of initiating exogenous insulin replacement therapy)

• Time from diagnosis to screening mixed meal tolerance test (MMTT) must be >= 1 year but =< 4 years

• Stable glycemic control per participant's physician

• HbA1c =< 7.5% (=< 58 mmol/mol)

• Non-fasting C-peptide > 0.017 nmol/L

• Stimulated peak C-peptide levels > 0.2 nmol/L from a 2-hour screening MMTT

• Positive for *04:01 allele, *04:02 allele and/or *04:04 allele at the human leukocyte antigen (HLA)-DRB1 gene locus

• Does not possess the protective HLA-DRB1*15:01-DQA1*01:02-DQB1*06:02 haplotype

• Adequate self-assessment of blood glucose values and recording of glucose values, and administered insulin doses as deemed sufficient by the participant's physician

• No diagnosis of type 1 diabetes related microvascular/macrovascular complications (e.g. nephropathy, retinopathy and neuropathy)

• Deemed acceptable for autologous cell collection (i.e. leukapheresis)

• Only for those who are naive to CGMD use: Deemed able to correctly use a CGM device following training session with a certified diabetes educator and manufacturer representative

• Must meet organ function criteria

Exclusion criteria

• Other investigational agents, biologics

• Anti-inflammatory therapy

  • Exception: Over-the-counter (OTC) anti-inflammatory agents (e.g. ibuprofen, Tylenol) are generally allowed. However, those requiring chronic OTC anti-inflammatory agents and unable to stop during mandated CGMD study visits will be excluded

• Systemic corticosteroids within 28 days prior to leukapheresis

• Systemic immunosuppressive therapy (e.g. cyclosporine-A, cyclophosphamide)

• Monoclonal antibody therapy

• Allergen immunotherapy within 28 days prior to leukapheresis

• Vaccine(s) within 28 days prior to leukapheresis

• Prior allogeneic organ transplant

• Beta-cell stimulants (e.g. sulfonylureas such as glimepiride), glucagon-like peptide-1 agonists, dipeptidyl peptidase-IV inhibitors (exception: Those with acute exposure to these agents during T1D misdiagnosis may be permitted per PI discretion)

• Insulin sensitizers (e.g. metformin, thiazolidinediones) within 2 months of leukapheresis

• History of insulin sensitizer use (e.g. metformin, thiazolidinediones) ≥ 2 months

• Other autoimmune/inflammatory disorders (exceptions: (i) Type 1 diabetes. (ii) Asymptomatic patients with incidental autoantibody titres may be permitted per PI discretion)

• Other autoimmune/inflammatory disorders (exception type 1 diabetes)

• Active infection requiring antibiotics and/or anti-virals

• Known history of HIV, HBV, HCV, HTLV, syphilis

• History of positive purified protein derivative (PPD) skin test

• History of atopy requiring systemic treatment and/or history of severe allergic reactions

• History or current malignancy

• Unstable cardiac disease

• History of vascular disease (e.g. deep vein thrombosis, stroke)

• Clinically significant uncontrolled illness

• Females only: pregnant or breastfeeding

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

6 participants in 1 patient group

Autologous Tolerogenic Dendritic Cell with Proinsulin Peptide (PIpepTolDC)

Experimental group

Description:

After completion of leukapheresis, patients receive a prime dose of PIpepTolDC intradermally (ID) on Day 0, followed by a boost dose of PIpepTolDC ID on Day 28.

Treatment:

Biological: Tolerogenic Dendritic Cell Vaccine